并非所有符合全身化疗条件的多形性胶质母细胞瘤（GBM）患者在前期手术和放疗后最终都会接受化疗。 GBM 患者的信息是从监测、流行病学和最终结果数据库中检索的。 2010年至2019年间接受前期手术或活检以及外照射放疗的患者有资格接受全身化疗。使用多变量逻辑回归和卡方检验评估可用的患者和肿瘤特征。在 16,682 名符合条件的患者中，92.1% 接受了全身化疗。与最低全身化疗利用率相关的特征包括脑干/小脑肿瘤 (P = 0.01)、既往诊断年份 (P = 0.001)、 ≥ 80 岁 (P < 0.001)、西班牙裔、非西班牙裔亚裔、太平洋岛民或黑人种族 (P < 0.001)、非伴侣身份 (P < 0.001) 和家庭收入中位数较低 (P = 0.006)。 原发肿瘤部位、诊断年份、年龄、种族、伴侣状况和家庭收入中位数与成年 GBM 患者省略全身化疗相关。© 2024。作者。

Not all patients with glioblastoma multiforme (GBM) eligible for systemic chemotherapy after upfront surgery and radiotherapy finally receive it. The information on patients with GBM was retrieved from the surveillance, epidemiology, and end results database. Patients who underwent upfront surgery or biopsy and external beam radiotherapy between 2010 and 2019 were eligible for systemic chemotherapy. The available patient and tumor characteristics were assessed using multivariable logistic regression and chi-squared test. Out of the 16,682 patients eligible, 92.1% underwent systemic chemotherapy. The characteristics linked to the lowest systemic chemotherapy utilization included tumors of the brain stem/cerebellum (P = 0.01), former years of diagnosis (P = 0.001), ≥ 80 years of age (P < 0.001), Hispanic, Non-Hispanic Asian, Pacific Islander, or Black race (P < 0.001), non-partnered status (P < 0.001), and low median household income (P = 0.006). Primary tumor site, year of diagnosis, age, race, partnered status, and median household income correlated with the omission of systemic chemotherapy in GBM in adult patients.© 2024. The Author(s).